Bookmark this page — the only place tracking real acceptance speed, FWCI and field-normalized citation data for this journal.

Journal decision profile

Cancer Discovery

Medicine · Biochemistry, Genetics and Molecular Biology
American Association for Cancer ResearchUnited StatespISSN 2159-8274eISSN 2159-8290
Checking system sharing availability.Visit homepage
7.12026 metrics scoreOpenAlex · CC0
138dmedian speedlatest 100 articles
$—publishing cost*verify with journal
Journal Metrics Score
i
Journal Metrics ScoreThe visible value is the 2026Journal Metrics Score: citations in the most recent complete year to the journal's works from the two prior years, divided by the number of those works — from OpenAlex open data (CC0).
2026
7.1

Journal Metrics Score 2026 · 20212024 window citedness 9.52.

Speed
i
SpeedMedian calendar days from manuscript received to accepted. It includes revision time and is not the journal's time to first decision.
PUBMED
138 days

Submission → acceptance · median · 100/100 recent articles.

APC / cost*
i
APC / cost*Costs are indicative and may exclude taxes, waivers, society discounts, or article-type charges. Always verify the journal's official website.
VERIFY
Not available

No reliable journal-level APC is cached. Cost is excluded from scoring.

At a glance

Journal decision profile

A visual summary for comparison—not a single black-box star rating.

Relative profile

Metrics ScoreThe 2026 Journal Metrics Score normalized within a comparable journal cohort.iSource outputLifetime journal-wide output rank among OpenAlex sources associated with the leading topic.iTop 10% shareShare of recent works in the field-normalized global top 10%.iMedian FWCITypical field-weighted citation impact, where 1.0 is the world expectation.iReview speedSubmission-to-acceptance timing, scored faster-is-better within the cohort.iOutput volumeRecent publication volume relative to comparable journals.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 Journal Metrics Score, normalized within a comparable journal cohort for this preview.
7.12026 · OPENALEX
Source output rank
i
Source output rankLifetime journal-wide output rank among OpenAlex sources associated with the journal’s leading topic.
#57 / 1,358LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersRecent works in the global top 10% after normalization by work type, year, and subfield.
25%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactMedian FWCI, where 1.0 is the expected citation level for comparable work.
0.14MEDIAN FWCI
Review speed
i
Review speedMedian submission-to-acceptance time from qualified PubMed records.
138 daysMEDIAN
Recent output
i
Recent outputAverage annual publication volume across the complete analysis window.
520 / yr2021–2024 AVG
Cost efficiency
i
Cost efficiencyNo score is assigned without a reliable journal-level cost.
NOT SCORED
Field-normalized top 10% share25%

519 of 2,078 works · same type, year & subfield

Field-normalized top 1% share9%

186 works · same type, year & subfield

Median FWCI0.14×

Below field-year expectation

Source output rank#57

of 1,358 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.14, so its typical recent paper runs about 86% below its field benchmark.

What does Top 10% Share mean?

25% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Submission to acceptance time (publication speed)

Among 100 recent articles with complete PubMed dates, the median time from received to accepted was 138 days. It includes revisions and is not the journal's time to first decision.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 20162025

5462016
5602017
5412018
4932019
5232020
5532021
5322022
5072023
4862024
4002025

Recent work-type mix

2,078 OpenAlex works · 20212024

Article98.2%
Erratum1%
Conference abstract0.5%
Paratext0.2%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works
NeoplasmsLung NeoplasmsCarcinoma, Non-Small-Cell LungBreast NeoplasmsPancreatic NeoplasmsAntineoplastic AgentsLeukemia, Myeloid, AcuteCarcinoma, Pancreatic DuctalMelanoma

Leading OpenAlex topics

20212024 works
Cancer Immunotherapy and Biomarkers138
Cancer Genomics and Diagnostics135
CAR-T cell therapy research120
Diverse Scientific and Economic Studies57
Lung Cancer Treatments and Mutations56
Acute Myeloid Leukemia Research54
Immune Cell Function and Interaction42
Immune cells in cancer40
Immunotherapy and Immune Responses36
Glioma Diagnosis and Treatment32
Methodology: OpenAlex snapshot 2026-08-09. FWCI, percentile badges, topics, and type mix use 2,078 works published 20212024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
OncologyQ1
Cancer ResearchQ1
Pulmonary and Respiratory MedicineQ1
Q1
Subfield Quartile
B1
CAS Block

Ranking and source check

#60
of 853 Oncology field journals
#60
among Q1 Oncology journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

Considering submitting to Cancer Discovery?

See if your manuscript fits this journal's recent focus before you commit to a shortlist.

Match my manuscript →

Journal Details

Total Articles
8,059
H-Index
304
Open Access
Hybrid (37% OA)
Subject Areas
OncologyCancer ResearchOncologyPulmonary and Respiratory Medicine
Back to Search